Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution in Turkey |
Bayman, Evrim
(Department of Radiation Oncology, Medical Faculty, Eskisehir Osmangazi University)
Etiz, Durmus (Department of Radiation Oncology, Medical Faculty, Eskisehir Osmangazi University) Akcay, Melek (Department of Radiation Oncology, Medical Faculty, Eskisehir Osmangazi University) Ak, Guntulu (Department of Chest Diseases, Medical Faculty, Eskisehir Osmangazi University) |
1 | Intaraphet S, Kasatpibal N, Siriaunkgul S, et al (2013). Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev, 14, 5355-60. 과학기술학회마을 DOI ScienceOn |
2 | Karam I, Jiang SY, Khaira M, Lee CW, Schellenberg D (2013). Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, (in press). |
3 | Murray N, Coy P, Pater JL, et al (1993). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 11, 336-44. |
4 | Rossi A, Di Maio M, Chiodini P, et al (2012). Carboplatinor Cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol, 30, 1692-8. DOI |
5 | Rossi A, Martelli O, Di Maio M (2013). Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev, 39, 498-506. DOI |
6 | Oguz A, Unal D, Tasdemir A (2013). Lack of any association between blood groups and lung cancer independent of histology. Asian Pac J Cancer Prev, 14, 453-6. 과학기술학회마을 DOI ScienceOn |
7 | Spiro SG, James LE, Rudd RM, et al (2006). Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer. A London lung cancer group multicenter randomized clinical trial and metaanalysis. J Clin Oncol, 24, 3823-30. DOI ScienceOn |
8 | Sun JM, Ahn YC, Choi EK, et al (2013). Phase III trial of concurrent thoracic radiotherapy with either first- or thirdcycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol, 24, 2088-92. DOI ScienceOn |
9 | Takada M, Fukuoka M, Kawahara M, et al (2002). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20, 3054-60. DOI ScienceOn |
10 | Turrisi AT 3rd, Kim K, Blum R, et al (1999). Twice-daily compared with once-daily thoracic radiation therapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340, 265-71. DOI ScienceOn |
11 | Warde P, Payne D (1992). Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol, 10, 890-5. |
12 | Wu C, Li F, Jiao SC (2012). Prognostic factors for survival of patients with extensive stage small cell lung cancer-a retrospective single institution analysis. Asian Pac J Cancer Prev, 13, 4959-62. 과학기술학회마을 DOI ScienceOn |
13 | Yee D, Hanson J, Butts C, et al (2010). Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma for the lung. Radiother Oncol, 96, 78-83. DOI |
14 | Zhao H, Gu J, Hua F, et al (2010). A meta-analysis of the timing of chest radiotherapy in patients with limited-stage small cell lung cancer. Zhongguo Fei Ai Za Zhi, 13, 892-7. |
15 | Zhao X, Sun X, Li Xl (2012). Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev, 13, 2873-7. 과학기술학회마을 DOI ScienceOn |
16 | Chen YT, Feng B, Chen LB (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev, 13, 3577-81. 과학기술학회마을 DOI ScienceOn |
17 | De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al (2006). Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small cell lung cancer. J Clin Oncol, 24, 1057-63. DOI ScienceOn |
18 | De Ruysscher D, Paris E, Le Pechoux C, et al (2011). A metaanaysis of randomized trials using individual patient data on the timing of chest radiotherapy in patients with limited stage small cell lung cancer. J Thorac Oncol, 6, S641-2. DOI |
19 | Erridge SC, Murray N (2003). Thoracic radiotherapy for limitedstage small cell lung cancer: issues of timing, volumes, dose, and fractionation. Semin Oncol, 30, 26-37. |
20 | Fried DB, Morris DE, Poole C, et al (2004). Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol, 22, 4837-45. DOI ScienceOn |
21 | Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. DOI ScienceOn |
22 | Huncharek M, McGarry R (2004). A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist, 9, 665-72. DOI |